Clinical Trial Update: Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the cancer response to the combination of abemaciclib and fulvestrant in women with recurrent endometrial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Adenocarcinoma of Endometrium | Phase 2 | Status: COMPLETED